3 Great Shares For A Beginners’ Portfolio: GlaxoSmithKline plc, Schroders plc & Latchways plc

GlaxoSmithKline plc (LON:GSK), Schroders plc (LON:SDR) and Latchways plc (LON:LTC) are three shares that could help transform your wealth.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

gskMulti-billionaire Warren Buffett, probably the world’s most famous and successful investor, follows a strategy of buying great businesses with a view to holding his shares ‘forever’.

What’s good enough for octogenarian Buffett should be good enough for an investor just starting out on the road to long-term wealth accumulation.

Today, I’m going to tell you why I think GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US), Schroders (LSE: SDR) and Latchways (LSE: LTC) are worth consideration for a beginner’s portfolio.

GlaxoSmithKline

Pharmaceuticals giant GlaxoSmithKline has a market capitalisation of £70bn, and is the fourth-largest company in the FTSE 100. The company is a ‘core’ holding for many investors.

Size, prodigious cash generation and the ‘non-cyclical’ nature of the pharma industry make Glaxo a relatively steady share through all economic conditions. The company has a great dividend history, and the prospective dividend yield is currently 5.7% at a share price of 1,434p. Reinvest the dividends to buy more shares year after year and the value of your investment should snowball over the long term.

Schroders 

Asset manager Schroders (founded in 1804) is also in the FTSE 100. With a market capitalisation of £6.5bn, Schroders may not be in the ‘megacap’ league of Glaxo, but I believe it has attractions for long-term investors.

The nature of Schroders’ business means its shares tend to exaggerate the returns of the wider market. Shareholders have to steel themselves when markets wobble, but because markets rise over the long term (multi-decades) the reward should be outsize returns if Schroders continues to do what it’s done successfully for over 200 years.

Unusually, the company has two classes of share: voting shares (ticker SDR) and non-voting shares (LSE: SDRC). Small private investors have little to gain from holding the voting shares. The non-voting shares are cheaper (currently 1,851p versus 2,435p for the voting shares), and provide a bigger dividend yield: 3.7% versus 2.8%.

Latchways

Smaller companies are considered inherently more risky than big companies — but they also have potential to grow faster. Furthermore, some smaller businesses have the kind of qualities Buffett looks for, and even a beginner may want to consider including a smattering of such shares in a portfolio.

Latchways, which has a market capitalisation of £109m, is the global leader in fall protection equipment for people working at height. Safety is not something employers can afford to skimp on. Latchways’ reputation as the number one — built over 30 years — and increasing safety regulation around the world, give the company plenty of scope to continue growing strongly.

Recent cyclical weakness is some of Latchways’ markets, notably commercial construction in parts of Europe, means investors today can buy the shares at a lower price (965p) than would otherwise have been the case. It also means that the prospective dividend yield (4.4%) is higher than usual.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

G A Chester has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. The Motley Fool UK owns shares of Latchways. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »